Close Menu
    Trending
    • Botswana opens consultations on proposed 33 percent hike now
    • PM Modi meets Prince and Princess of Wales for climate talks
    • Ebola adds 60 cases in a day as Congo deaths hit 5,568
    • Dubai Airports expects over 70 million guests in 2026
    • Rand slips toward R17 as inflation and weak growth cloud outlook
    • Tüyap highlights MENA sourcing opportunities at the carpet expo in Istanbul
    • Chevron Signs 3-Year Agreement with UptimeAI, Scaling Expertise to Enhance Asset Reliability and Operational Efficiency
    • Over 9 million visitors lift Tunisia tourism income 3.4%
    • Home
    • Contact Us
    Beyrout NewsBeyrout News
    Friday, November 20
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Beyrout NewsBeyrout News
    Home » FDA approves Cobenfy, the first schizophrenia drug in 30 years
    Health

    FDA approves Cobenfy, the first schizophrenia drug in 30 years

    September 30, 2024
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    MENA Newswire News Desk: The U.S. Food and Drug Administration (FDA) has approved Cobenfy, a new medication for the treatment of schizophrenia, marking the first major advance in this area in more than three decades. Cobenfy, developed by Bristol Myers Squibb, is a twice-daily oral medication that combines two drugs, xanomeline and trospium chloride, offering a new therapeutic option for managing schizophrenia symptoms like hallucinations, delusions, and disorganized thinking.

    FDA approves Cobenfy, the first schizophrenia drug in 30 years

    The FDA’s approval of Cobenfy offers fresh hope for millions of people living with schizophrenia, a severe mental health disorder that affects approximately 24 million people globally. According to Dr. Tiffany Farchione, Director of the Division of Psychiatry at the FDA’s Center for Drug Evaluation and Research, the approval breaks new ground in the treatment of this condition. “This is the first new approach to treating schizophrenia in decades, offering a valuable alternative to the antipsychotic medications that have been standard for so long,” she said.

    Most existing schizophrenia treatments focus on altering dopamine levels in the brain, a neurotransmitter linked to mood and behavior. Cobenfy, however, targets acetylcholine receptors, a different pathway in the brain that influences memory, learning, and attention. This novel mechanism of action is particularly important for patients who experience side effects such as weight gain, drowsiness, or movement disorders from traditional antipsychotics.

    In clinical trials, Cobenfy demonstrated significant effectiveness in reducing schizophrenia symptoms, with only 6% of patients discontinuing the drug due to side effects, compared to 20-30% with older medications. Dr. Samit Hirawat, Chief Medical Officer at Bristol Myers Squibb, hailed the results as a major improvement over previous treatment options.

    Common side effects of Cobenfy include nausea, constipation, and increased heart rate, according to the FDA’s approval notice. However, these side effects were notably less severe than those caused by earlier medications. Dr. Leslie Citrome, a professor of psychiatry at New York Medical College, emphasized that the drug could benefit patients who cannot tolerate the side effects of current treatments.

    Schizophrenia is a lifelong mental illness that typically begins in late adolescence or early adulthood and is characterized by distorted thinking, behavior, and emotions. It often leads to significant challenges in daily functioning, impacting work and relationships. The approval of Cobenfy could represent a breakthrough for patients who have struggled with available treatments for years. Cobenfy is expected to be available for prescription by the end of October, according to Adam Lenkowsky, Executive Vice President at Bristol Myers Squibb. Ongoing studies are also exploring its potential for treating other conditions, including Alzheimer’s disease and bipolar disorder.

    Related Posts

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026

    Yellow fever kills 18 across nine African nations, WHO says

    November 7, 2026

    Dengue kills 173 in October as Bangladesh toll climbs to 418

    November 2, 2026

    Ebola deaths in DR Congo reach 5,340, fatality rate at 51.6%

    November 2, 2026

    Ebola death toll in DR Congo nears 4,900 as cases pass 10,000

    October 28, 2026
    Latest News

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales for climate talks

    November 19, 2026

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026
    © 2026 Beyrout News | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.